COVID-19 and Psoriasis: Understanding the Impact and Vaccine Safety

April 17, 2024

Featured image for “COVID-19 and Psoriasis: Understanding the Impact and Vaccine Safety”

The COVID-19 pandemic created massive global upheaval and revealed extensive interconnectivity between various health conditions. For those living with immune-mediated diseases like psoriasis, viral triggers can wreak havoc. This article examines the emerging evidence on COVID-19 interplay with psoriasis onset and flares.

COVID-19 Infection and Inflammation

SARS-CoV-2, the novel coronavirus causing COVID-19 illness, leads to widespread effects beyond just respiratory impacts. Systemic inflammation and cytokine elevations likely underpin many lingering symptoms and downstream effects.

In moderate to severe infections, cytokine and chemokine levels correlate with greater disease severity. The cytokine release syndrome generating inflammation could theoretically activate underlying autoimmune conditions like psoriasis.

Stress from being ill may also amplify immune dysfunction. hospitalization stays disrupt medication adherence further increasing risks. Understanding connections between viral infection and inflammatory disease flares becomes imperative.

Early epidemiological data reveals nearly a third of psoriasis patients surveyed reported disease worsening after COVID-19 infection, compared to only 6% improving. Another study found psoriasis patients 50% more likely to experience COVID-19 complications versus the general populace when controlling for medications used.

Observational data consistently demonstrate particularly within 6 weeks post-infection, those with psoriasis see substantial exacerbations from COVID-19 illness. Interestingly, asymptomatic infections don’t emerge as clearly linked with flares, hinting at infection severity being an important factor.

Plausible explanations for these epidemiological associations include viral elicitation of cytokine pathways known to drive psoriasis also playing a role in COVID-19 pathology.

COVID-19 Vaccines and Psoriasis: Mixed Signals

Amidst the colliding pandemics of COVID-19 and misinformation, viral immunizations faced undue scrutiny. For those with psoriasis, questions emerged regarding risks of new mRNA platforms and potential disease flares.

Early case reports documented psoriasis exacerbations following COVID-19 vaccination – either mRNA or inactivated vaccines. Proposed mechanisms include stimulating interferon pathways or adjuvants provoking excessive inflammation.

However, larger data sets find scant evidence of increased psoriasis flares post-immunization when accounting for natural fluctuation and compared to infection itself. Those on immunosuppressants also demonstrate similar antibody responses.

Overall the most dangerous aspect for those with psoriasis remains COVID-19 infection. Data should reassure that vaccines provide important protection, although uncertainty persists on rare risks.

Individual Considerations for Psoriasis Management During COVID-19

Caring for psoriasis through the shifting pandemic landscape proves challenging with evolving evidence. Optimizing outcomes requires personalization balancing relative risks and benefits.

Preventing Infection

Minimizing infection likelihood is paramount. Beyond societal measures, high quality masks, avoiding crowds, and maximizing ventilation in public spaces helps reduce risk. Treating any suspected respiratory illness urgently also wise.

Monitoring Medications

Collaborating closely with your healthcare provider to make informed choices about medications vital. Those on immunosuppressants need antibody testing after vaccination to confirm response. Being attuned to changes and ready to adapt approaches critical.

Controlling Stress and Triggers

Stress substantially contributes to flares. Finding healthy coping outlets, connecting with your support systems however possible, and practicing self-care all help durable mental health. Reducing other flare triggers simultaneously also useful.

While questions remain on explaining the intersection of COVID-19, vaccines and psoriasis, maintaining access to quality care and medications during the pandemic facilitates better overall outcomes.

Frequently Asked Questions About COVID-19 and Psoriasis

Can COVID-19 trigger new psoriasis in someone without psoriasis previously?

Maybe in rare cases, but unlikely to directly cause brand new psoriasis without any prior genetic predisposition or family history. However, COVID-related stress and medications could elicit onset of latent psoriasis tendencies. Most reported cases note exacerbation of existing mild or moderate psoriasis.

Do mRNA vaccines pose more psoriasis flare risk than other kinds?

Likely not when parsing larger data sets – both mRNA and inactivated COVID platforms saw occasional associated flares early on. Any immune stimulating vaccine can theoretically activate underlying autoimmunity. Overall flare rates appear similar with proper post-vaccination monitoring and treatment.

Should I stop my psoriasis biologic if I get COVID-19?

Usually not, discuss with your healthcare provider. Stopping biologics may limit medication options if hospitalized, raising risks. Careful consideration of immune effects in both directions vital. Expanded vaccine access and antiviral therapies now available also change the equation.

Can getting COVID lead to developing psoriatic arthritis?

Unclear presently if COVID specifically could trigger additional musculoskeletal manifestations alone without any prior psoriatic arthritis changes. However cytokine elevations may exacerbate joint inflammation resulting in worsening related pain, stiffness, or damage. Further study needed isolating COVID’s role.

Will we see more or less psoriasis flares as COVID variants like Omicron continue evolving?

Hard to predict based on limited longer-term follow-up data presently. If variants keep demonstrating COVID precipitation of acute flares, then infection waves would correlate with spikes of psoriasis patients needing urgent care. On the other hand, potentially milder variants eliciting less cytokine storms could show fewer exacerbations. Continued vigilance prudent.

Key Takeaways on COVID-19 and Psoriasis

  • Strong evidence links COVID-19 infection with psoriasis flares
  • Stress, hospitalization may additionally worsen disease
  • Vaccines have low risks of flares in larger data sets
  • Personalized care decisions vital amid shifting pandemic
  • Reducing infection risk should remain high priority

Next Steps for Research at the Intersection of COVID-19 and Psoriasis

Many unknowns persist investigating connections between COVID-19 and psoriasis onset or flares. Areas needing illumination by ongoing research include:

  • Comparisons of flare risks between COVID variants
  • Stratification of flare likelihood by psoriasis subtype and severity
  • Analysis of flare differences from infection versus vaccines
  • Exploration of genetic or immune response markers
  • Long term impacts on psoriasis disease course
  • Head-to-head trials of emerging COVID therapeutics
  • Updated recommendations on managing medications peri-COVID

While broad epidemiological patterns offer insights, appreciating additional nuance should continue optimizing care for patients navigating these colliding conditions.


The intricate immunological dance between COVID-19 and psoriasis remains complex. Observational data consistently demonstrates viral infection often exacerbating psoriasis inflammation. Stress, hospitalization stays, and shifting treatment options during illness may contribute additional risks. Questions linger whether COVID-19 vaccination poses any substantive flare threat, but benefits likely outweigh rare uncertain links. Those with psoriasis must receive personalized guidance from their healthcare teams accounting for multifaceted considerations when making decisions amid this unprecedented pandemic landscape. Ultimately keeping psoriasis under optimal control facilitates weathering the erratic virus storm.


  • Amatore, Federica et al. “Psoriasis and COVID-19: a review of clinical features and pharmacological management.” Immunology letters vol. 236 (2021): 68-84. doi:10.1016/j.imlet.2021.07.004.
  • Sanchez, Adan et al. “Exacerbation of psoriasis in patients with COVID-19: A case series.” Journal of the American Academy of Dermatology vol. 83,6 (2020): e297-e298. doi:10.1016/j.jaad.2020.07.093.
5/5 - (1 vote)

Related articles


Cold Plasma System

The world's first handheld cold plasma device

Learn More

Made in USA